This is the a Soviet-designed, high-altitude air defense system S-75 Dvina also known as the SA-2 Guideline. Instructions available at www.snakebyte.dk/lego/instructions/military/s-75_dvina/in...

The instructions are created by Knud A. Albrechtsen

 

Size: 1/32

Color: Dark Gray and Light Bluish Gray

 

A United Launch Alliance Atlas V rocket with Boeing’s CST-100 Starliner spacecraft aboard is seen after being rolled out of the Vertical Integration Facility to the launch pad at Space Launch Complex 41 ahead of the Orbital Flight Test-2 (OFT-2) mission, Wednesday, May 18, 2022 at Cape Canaveral Space Force Station in Florida. Boeing’s Orbital Flight Test-2 will be Starliner’s second uncrewed flight test and will dock to the International Space Station as part of NASA's Commercial Crew Program. The mission, currently targeted for launch at 6:54 p.m. ET on May 19, will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Joel Kowsky)

Valles Marineris, seen at an angle of 45 degrees to the surface in near-true colour and with four times vertical exaggeration. The image covers an area of 630 000 sq km with a ground resolution of 100 m per pixel. The digital terrain model was created from 20 individual HRSC orbits, and the colour data were generated from 12 orbit swaths. The largest portion of the canyon, which spans right across the image, is known as Melas Chasma. Candor Chasma is the connecting trough immediately to the north, with the small trough Ophir Chasma beyond. Hebes Chasma can be seen in the far top left of the image.

 

The image was first published in 2009 in the ESA science monograph Mars Express: The Scientific Investigations.

 

For further information and a higher resolution of this image, please click here.

 

Credit: ESA/DLR/FU Berlin (G. Neukum), CC BY-SA 3.0 IGO

 

Copyright Notice:

 

This work is licenced under the Creative Commons Attribution-ShareAlike 3.0 IGO (CC BY-SA 3.0 IGO) licence. The user is allowed to reproduce, distribute, adapt, translate and publicly perform this publication, without explicit permission, provided that the content is accompanied by an acknowledgement that the source is credited as 'ESA/DLR/FU Berlin’, a direct link to the licence text is provided and that it is clearly indicated if changes were made to the original content. Adaptation/translation/derivatives must be distributed under the same licence terms as this publication. To view a copy of this license, please visit creativecommons.org/licenses/by-sa/3.0/igo/

Red-Footed Booby on a rusty old section of the seawall. Tern Island in the French Frigate Shoals, Hawaii.

 

Camera: Olympus OM-1

Lens: Olympus OM-System S Zuiko MC Auto-Zoom f/4 35-70mm. Yellow filter.

Film: Adox HR-50

Developer: Beerenol (Rainier Beer)

With the decline of the Greco-Roman Federation and the decreasing need for large quantities of VCS, the URE commissioned a new design, based around the Grouse II, that would be able to hold their own against multiple enemy VCS. Thus, the Grouse III (commonly known as the "Crusader") was born.

 

The Grouse III shares almost no physical elements with its predecessor, except for some parts of its inner structural design. It is a much heavier VCS, due mostly in part to its thicker armor and considerably more extensive array of equipment. In addition, the Grouse III has a much more comfortable and complex cockpit, alloying the pilot greater control over the system.

 

The Grouse III's primary weapon is a elite-issue 09R-Gunbow, a weapon that can convert between a machine gun (higher firing rate) and an energy crossbow (more accuracy). It also carries a hefty vibrotech sword, and a carbon-based shield. The shield can fire multiple small rockets. In addition, there are to small machine guns in the cranial unit, and a small semi-automated turret on the system's left shoulder. Two small rockets can be fired from each shoulder as well.

 

Here's the inevitable follow-up to the Grouse II. I started with the cockpit, since I wanted it to be as detailed a possible. The original design for it was even larger than the current one, which is already too bulky. Because of the bulk, I opted for a more medieval knight-inspired mech, an idea which suited it quite well.

The flowers at the Depot restaurant in Seaview, Washington, are spectacular, as these photos show.

 

If I want to enjoy flowers like these, I'll either have to go to the Depot or look at these photos. The deer love to eat flowers, and who wouldn't? They're a delight for the eyes and the palate.

======================

The History of the DEPOT Restaurant, located in the historic Seaview train depot

 

Seaview’s popularity as a vacation site began in the 1870’s when families would arrive by horseback, wagon, stagecoach and steamer to camp in the Willows, north of Cape Disappointment. The transition of Seaview from campground to resort is credited to Jonathon L. Stout who is believed to have come to the Peninsula as a barrel maker from Ohio in 1859. He married Ann Elizabeth Gearhart, daughter of Oregon’s Phillip Gearhart in 1860.

 

He was postmaster of Ilwaco, operated a liquor store and stagecoach line. They homesteaded 153.5 acres near the Willows in 1880 to create a summer retreat that was registered as “Sea View” at the Oysterville courthouse in 1881.

 

Lewis Alfred Loomis, one of the peninsula’s founding father’s secured a mail contract between Astoria, Oregon and Olympia, the capital of Washington. The slowness of the stage line used, convinced Loomis that he should build a railroad to handle his business.

 

Construction of his railroad, the Ilwaco Railroad and Navigation Company, began in March, 1888 at the Ilwaco wharf, which was the central place of its business.

 

Steamers could only reach the wharf after the tide was in mid-flood. So train departures were successively later over a month’s time. It is likely that the Ilwaco line was the only organized railroad to operate by a tide table, thus its nickname, the “Clamshell Railroad”.

 

The system’s first depot was built in Ilwaco not far from the wharf. Frank Strauhal, a summer camper, purchased Stout’s store and bathhouse in Seaview. He offered the railroad a lot, if a depot was erected on it. The line accepted and thus a wooden platform shed was built as a train stop on the current Seaview Depot site. The railroad reached Long Beach by July 1888. Track laying continued at a leisurely pace, terminating at Nahcotta, thirteen and a half miles north of Ilwaco.

 

In addition to the mail contract, passenger business and freight helped the railroad prosper. Over a thousand sacks of oysters were transported each week from Nahcotta to Ilwaco. From Ilwaco they were carried by the General Canby to Astoria for shipment to market in San Francisco. The freight charge from Nahcotta to Astoria was seventy-five cents a sack. Thursday was oyster day. Citizens with business in Astoria generally avoided that day.

 

In 1900, Loomis retired selling to a subsidiary of Union Pacific, the Oregon Railroad and Navigation Company. Equipment was immediately improved and train crews were required to wear uniforms.

 

At a 1905 Directors’ meeting the construction of a regular depot to replace the platform shed at Seaview was authorized. You are sitting in that building today.

 

The railroad continued in operation until September 10, 1930, when car ferries and highways brought most of us here. The only remaining are the Long Beach and Seaview train depot buildings.

 

The Depot Restaurant today:

 

The Depot Restaurant features fine dining with international wines, on-tap microbrews, a display kitchen, heated outdoor deck, and special events ranging from wine dinners to Jazz events. This Seaview train depot has more than stood the test of time!

 

Enjoy contemporary and historic photos of our Seaview train depot on our page all about historic Seaview, Washington.

  

A United Launch Alliance Atlas V rocket with Boeing’s CST-100 Starliner spacecraft aboard is seen on the launch pad at Space Launch Complex 41 ahead of the Orbital Flight Test-2 mission, Wednesday, May 18, 2022 at Cape Canaveral Space Force Station in Florida. Boeing’s Orbital Flight Test-2 will be Starliner’s second uncrewed flight test and will dock to the International Space Station as part of NASA's Commercial Crew Program. The mission, currently targeted for launch on 6:54 p.m. ET on May 19, will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Joel Kowsky)

A United Launch Alliance Atlas V rocket with Boeing’s CST-100 Starliner spacecraft aboard is seen as it is rolled out of the Vertical Integration Facility to the launch pad at Space Launch Complex 41 ahead of the Orbital Flight Test-2 (OFT-2) mission, Wednesday, May 18, 2022 at Cape Canaveral Space Force Station in Florida. Boeing’s Orbital Flight Test-2 will be Starliner’s second uncrewed flight test and will dock to the International Space Station as part of NASA's Commercial Crew Program. The mission, currently targeted for launch at 6:54 p.m. ET on May 19, will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Joel Kowsky)

A United Launch Alliance Atlas V rocket with Boeing’s CST-100 Starliner spacecraft aboard is seen as it is rolled out of the Vertical Integration Facility to the launch pad at Space Launch Complex 41 ahead of the Orbital Flight Test-2 (OFT-2) mission, Wednesday, May 18, 2022 at Cape Canaveral Space Force Station in Florida. Boeing’s Orbital Flight Test-2 will be Starliner’s second uncrewed flight test and will dock to the International Space Station as part of NASA's Commercial Crew Program. The mission, currently targeted for launch at 6:54 p.m. ET on May 19, will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Joel Kowsky)

Alcatraz

 

Early Years as a Military Prison

 

In 1775, Spanish explorer Juan Manuel de Ayala (1745-97) mapped and named rugged Alcatraz Island, christening it La Isla de los Alcatraces, or Island of the Pelicans, due to its large population of sea birds. Seventy-five years later, in 1850, President Millard Fillmore (1800-74) signed an order reserving the island for military use. During the 1850s, a fortress was constructed on Alcatraz and some 100 cannons were installed around the island to protect San Francisco Bay. Also during this time, Alcatraz became home to the West Coast’s first operational lighthouse.

By the late 1850s, the U.S. Army had begun holding military prisoners at Alcatraz. Isolated from the mainland by the cold, strong waters of San Francisco Bay, the island was deemed an ideal location for a prison. It was assumed no Alcatraz inmate could attempt to escape by swimming and survive.

 

During its years as a military prison, the inmates at Alcatraz included Confederate sympathizers and citizens accused of treason during the American Civil War (1861-65). Alcatraz also housed a number of “rebellious” American Indians, including 19 Hopis from the Arizona Territory who were sent to the prison in 1895 following land disagreements with the federal government. The inmate population at Alcatraz continued to rise during the Spanish-American War (1898).

 

During the early 20th century, inmate labor fueled the construction of a new cellhouse (the 600-cell structure still stands today) on Alcatraz, along with a hospital, mess hall and other prison buildings. According to the National Park Service, when this new complex was finished in 1912 it was the world’s largest reinforced concrete building.

Doing Time as a Federal Prison: 1934-63

 

In 1933, the Army relinquished Alcatraz to the U.S. Justice Department, which wanted a federal prison that could house a criminal population too difficult or dangerous to be handled by other U.S. penitentiaries. Following construction to make the existing complex at Alcatraz more secure, the maximum-security facility officially opened on July 1, 1934. The first warden, James A. Johnston (1874-1954), hired approximately one guard for every three prisoners. Each prisoner had his own cell.

 

The Federal Bureau of Prisons (BOP) viewed Alcatraz as “the prison system’s prison,” a place where the most disruptive inmates could be sent to live under sparse conditions with few privileges in order to learn how to follow rules (at which point, they could be transferred to other federal prisons to complete their sentences). According to the BOP, Alcatraz typically held some 260 to 275 prisoners, which represented less than 1 percent of the entire federal inmate population.

 

The federal prison on Alcatraz Island in the chilly waters of California’s San Francisco Bay housed some of America’s most difficult and dangerous felons during its years of operation from 1934 to 1963. Among those who served time at the maximum-security facility were the notorious gangster Al “Scarface” Capone (1899-1947) and murderer Robert “Birdman of Alcatraz” Stroud (1890-1963). No inmate ever successfully escaped The Rock, as the prison was nicknamed, although more than a dozen known attempts were made over the years. After the prison was shut down due to high operating costs, the island was occupied for almost two years, starting in 1969, by a group of Native-American activists. Today, historic Alcatraz Island, which was also the site of a U.S. military prison from the late 1850s to 1933, is a popular tourist destination.

 

Source: www.history.com/topics/alcatraz

Aston Martin V8 Vantage S Roadster (2013-18) Engine 4735cc AJ7 Quad Cam 32v V8

Production 6,231 V8 Roadsters

Registration Number JAU 8821 (Cherished number, now transferred to a DB11, originally allocated in Nottingham)

 

ASTON MARTIN SET

 

www.flickr.com/photos/45676495@N05/sets/72157623759800132...

 

Introduced at the 2005 Geneva Auto Show The two seat, two -door coupé had a bonded aluminium structure for strength and lightness the Coupe features a hatchback style rear tailgate.

 

The V8 Vantage was initially powered by a 4.3 L (4300 cc) quad-cam 32-valve V8 which produced 380 hp and 302 lb·ft of torque However models produced after 2008 had a 4.7 litre 420 hp V8. Though based loosely on Jaguar's AJ-V8 engine architecture, this engine was unique to Aston Martin and featured race-style dry-sump lubrication, which enabled it to be mounted low in the chassis for an improved center of gravity. The cylinder block and heads, crankshaft, connecting rods, pistons, camshafts, inlet and exhaust manifolds, lubrication system, and engine management were all Aston Martin designs and the V8 engine was assembled by hand at the AM facility in Cologne, Germany.

 

The original V8 Vantage could accelerate to 60 mph (97 km/h) in 4.7 seconds topping out at 175 mph , Vantages with the enhanced 400 HP version of the 4.3 L V8 engine

 

The V8 Vantage retailed for £79,000 in 2006

 

The V8 Vantage S was unveiled in January 2011as a more potent version of the V8 Vantage available as both Coupé and Roadster. Powered by the same 4.7-litre AJ37 V8 found in the base Vantage, but with improved intake airflow, new mufflers, and new programming that keeps the exhaust system's bypass valves open for longer. The 4.7-litre V8 engine has been modified to deliver a peak power of 430 bhp giving a maximum speed of 189mph. he aerodynamic enhancements include a deeper front bumper with carbon fibre splitter, larger side sills, a carbon fibre diffuser, larger tailgate new wheels

 

Production of the V8 Vantage ended in 2017 while production of the V12 Vantage continued until 2018. In November 2017, Aston Martin unveiled a new redesigned Vantage.

 

The new model was unveiled in 2017 and began production in 2018.

 

Thanks for a stunning 61,328,365 views

 

Diolch am olygfa anhygoel, 61,328,365 hoblogaeth y Lloegr honno dros y Mynyddoedd

 

Shot 30-07-2017 exiting the 2017 Silverstone Classic REF 129-062

  

Boeing and NASA teams participate in a mission dress rehearsal to prepare for the landing of the Boeing CST-100 Starliner spacecraft in White Sands, New Mexico, Monday, May 23, 2022. Boeing’s Orbital Flight Test-2 (OFT-2) is Starliner’s second uncrewed flight test to the International Space Station as part of NASA's Commercial Crew Program. OFT-2 serves as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Bill Ingalls)

Inside the Astrotech Space Operations Facility in Titusville, Florida, the United Launch Alliance (ULA) payload fairing has been secured around NASA’s Lucy spacecraft on Sept. 30, 2021. The payload fairing will encapsulate and protect the spacecraft during launch and ascent. Lucy is scheduled to launch no earlier than Saturday, Oct. 16, on a ULA Atlas V 401 rocket from Space Launch Complex 41 at Cape Canaveral Space Force Station. NASA’s Launch Services Program based at Kennedy Space Center is managing the launch. Over its 12-year primary mission, Lucy will explore a record-breaking number of asteroids, flying by one asteroid in the solar system’s main belt and seven Trojan asteroids. Additionally, Lucy’s path will circle back to Earth three times for gravity assists, making it the first spacecraft ever to return to the vicinity of Earth from the outer solar system. Photo credit: NASA/Ben Smegelsky

NASA image use policy.

 

Heritage Class Race Rover

 

Firm belivers in peaceful scientific exploration, the Unitron system's spacemen continued to find new uses for Magnetonium, the rare element discovered and mined in the M-Tron system. Powered by a magnetonium steam turbine and featuring oversized primary drive wheels, the Neon Urchin race rover was a torque monster. Another prominent feature is the dual guidance arrays flanking the open cockpit, giving the urchin its name.

 

For more on the origin of the GTR-RL, watch the video trailer.

 

The GTR-RL is organized into three classes of racing rovers.

 

Heritage class rovers are built using only elements available to the theme of the racer. (i.e. a space police 1 race rover would be built using only parts from the 1989 space police theme.) Heritage class rovers represent Lego space themes up through the insectoid theme of 1998-99.

 

Modern class rovers are built in the same way, but represent Lego space themes from the 2001 theme Life on Mars, through present day space themes.

 

Unlimited class rovers are built with an unrestricted element palette and can represent Collectible Minifig themes or fan themes such as Pinktron and Suntron, etc

 

Check out more Race Rovers

The crew access arm is seen as it swings into position for Boeing’s CST-100 Starliner spacecraft atop a United Launch Alliance Atlas V rocket at the launch pad at Space Launch Complex 41 ahead of the Orbital Flight Test-2 (OFT-2) mission, Thursday, July 29, 2021 at Cape Canaveral Space Force Station in Florida. Boeing’s Orbital Flight Test-2 will be Starliner’s second uncrewed flight test and will dock to the International Space Station as part of NASA's Commercial Crew Program. The mission, currently targeted for launch at 2:53 p.m. EDT Friday, July 30, will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Joel Kowsky)

Technology image of the week is this shining face of the Mercury Magnetosphere Orbiter, Japan’s contribution to the BepiColombo mission to the Solar System’s innermost planet.

 

The octagonal spacecraft is seen here at ESA’s test centre in the Netherlands, where it is being tested alongside the other elements of this dual-spacecraft mission.

 

During cruise, it will sit above ESA’s Mercury Planetary Orbiter at the top of the BepiColombo stack, to be launched in April 2018. The Mercury Transfer Module will deliver them to Mercury using highly efficient electric propulsion .

 

While ESA’s craft will go into a 480 x 1500 km mapping orbit around Mercury, Japan’s will enter a highly elliptical 590 x 11 640 km orbit to study the planet’s environment and its magnetic field.

 

The two spacecraft employ differing strategies to cope with the temperatures in excess of 350°C involved in operating around the closest world to the Sun. Japan’s octagonal orbiter will spin 15 times per minute to distribute heat evenly across its surface. But since it cannot spin during BepiColombo’s seven-year journey from Earth, it will be protected within the Magnetospheric Orbiter Sunshield.

 

ESA’s orbiter, meanwhile, will maintain a steady attitude, covered with high-temperature insulation with a deep space-facing radiator behind protective louvres that will dump waste heat into space.

 

Credit: Airbus DS GmbH 2015

see it in motion at: n-e-r-v-o-u-s.com/projects/sets/zoetropes/

 

nylon 3D printed by Selective Laser Sintering, MDF, electronics, LEDs

 

A tree-like form with two leaves grows as the disc spins. The zoetrope illustrates Nervous System’s leaf venation inspired algorithm, hyphae, as it grows across 3D surfaces.

 

30.5 x 30.5 x 21 inches

Central hall of metro station Ploshchad Vosstaniya on the Kirovsko-Vyborgskaya Line (Line 1), Ploshchad Vosstaniya, Saint Petersburg, Russia

 

Some background information:

 

The Saint Petersburg Metro is the underground railway system of the city of Saint Petersburg. It has been open since 15th November 1955. Formerly known as the V.I. Lenin Order of Lenin Leningrad Metropoliten, the system exhibits many typical Soviet designs and features exquisite decorations and artwork making it one of the most attractive and elegant metros in the world, maybe only excelled by the Moscow Metro. Due to the city's unique geology, the Saint Petersburg Metro is also one of the deepest metro systems in the world and the deepest by the average depth of all the stations. The system's deepest station, Admiralteyskaya, is located 86 metres below ground. Serving 2.1 million passengers daily (resp. 763.1 million passengers per year), the Saint Petersburg Metro is the 19th busiest metro system in the world.

 

Ploshchad Vosstaniya is a metro station on the Kirovsko-Vyborgskaya Line of Saint Petersburg Metro. It is one of the system's original stations, opening on 15th November 1955. It is a deep underground pylon station at 58 metres (190 feet) depth. The main surface vestibule is situated on Ploshchad Vosstaniya (in English: "Uprising Square"), which gives its name to the station. The metro station Ploshchad Vosstaniya is connected to the metro station Mayakovskaya of the Nevsko-Vasileostrovskaya Line via a transfer corridor and a set of escalators. St.Petersburg-Glavny, also known as Moskovsky railway station (where all trains to or from Moscow depart or arrive), is located on the other side of the square, right opposite the metro station. Moskovsky railway station is one of Saint Petersburg’s six main railway stations.

 

In Saint Petersburg’s history, the question of building an underground transport system arose several times, the first time in 1820, when the idea was hatched to build an underground road in a tunnel. By the end of the 19th century, certain interested parties began discussing the possibility of opening the Russian Empire's first metropolitan railway system. Almost all pre-revolutionary designs featured the concept of an elevated metro system, similar to the Paris or Vienna metros. However, as was later discovered through the experience of operating open (ground-level) metro lines in the city, such schemes would likely have resulted in a poor metro service. Unfortunately, at the time, Russian engineers did not have sufficient expertise or technical resources for the construction of deep underground tunnels through the bedrock located far beneath St Petersburg. Hence, it was finally Moscow that got the first underground railway system in the Soviet Union in 1935.

 

In 1938 the question of building a metro for Saint Petersburg (by then renamed to Leningrad), resurfaced again. The initial project was designed by the Moscow institute 'Metrogiprotrans', but on 21st January 1941, "Construction Directorate № 5 of the People's Commissariat" was founded as a body to specifically oversee the design and construction of the Leningrad Metro. By April 1941, 34 shafts for the initial phase of construction had been finished. During the Second World War construction works were frozen due to severe lack of available funding, manpower and equipment. At this time, many of the metro construction workers were employed in the construction and repair of railheads and other objects vital to the besieged city.

 

In 1946 Lenmetroproyekt was created, to finish the construction of the metro first phase. A new version of the metro project, devised by specialists, identified two new solutions to the problems to be encountered during the metro construction. Firstly, stations were to be built at a level slightly raised above that of normal track so as to prevent drainage directly into them, whilst the average tunnel width was to be reduced from the 6 metres (20 feet) standard of the Moscow Metro to 5.5 metres (18 feet).

 

On 3rd September 1947, construction in the Leningrad subway began again and eight years later, on 7 October 1955, the electricity was turned on in the metro l. On 15th November 1955, the subway grand opening was held, with the first seven stations being put into public use. These stations later became part of the Kirovsko-Vyborgskaya Line, connecting the Moscow Rail Terminal in the city centre with the Kirovsky industrial zone in the southwest. Subsequent development included lines under the Neva River in 1958, and the construction of the Vyborgsky Radius in the mid-1970s to reach the new housing developments in the north. In 1978, the line was extended past the city limits into the Leningrad Oblast.

 

By the time of the USSR's collapse, the Leningrad Metro comprised 54 stations and 94.2 kilometres (58.5 miles) of track. But development even continued in the modern, post-Soviet period. Today, the Saint Petersburg metro comprises five lines with altogether 69 stations and 118,6 kilometres (74 miles) of track. However, the present state is not meant to be the end of the story. Plans have been made to extend the Saint Petersburg Metro to nine lines with altogether 126 stations and 190 kilometres (118 miles) of track. But delays due to the difficult geology of the city's underground and to the insufficient funding have cut down these plans to 17 new stations and one new depot until 2025. At the same time, there are several short and mid-term projects on station upgrades, including escalator replacements and lighting upgrades.

 

On 3rd April 2017, a terrorist bombing caused an explosion on a train between Sennaya Ploshchad and Tekhnologicheski Institut stations, on the Line 2. 14 people died and over 50 sustained injuries, while Russian president Vladimir Putin was in the city, when the attack happened. On the same day, Russia's National anti-terrorist unit defused another explosive device at Ploshchad Vosstaniya station (which you can see on this picture).

 

Saint Petersburg (in Russian: Санкт-Петербу́рг) is Russia's second-largest city after Moscow, with currently 5.3 million inhabitants, part of the Saint Petersburg agglomeration with a population of 6.2 million (2015). An important Russian port on the Baltic Sea, it has a status of a federal city. Saint Petersburg is also the fourth-largest city in Europe, only excelled by Istanbul, London and Moscow. Other famous European cities like Paris, Berlin, Rome and Madrid are smaller. Furthermore, Saint Petersburg is the world’s northernmost megapolis and called "The Venice of the North", due to its many channels that traverse the city.

 

Situated on the Neva River, at the head of the Gulf of Finland on the Baltic Sea, it was founded by Tsar Peter the Great on 27th May 1703. On 1st September 1914, the name was changed from Saint Petersburg to Petrograd, on 26 January 1924 to Leningrad, and on 7 September 1991 back to Saint Petersburg. Between 1713 and 1728 and again between 1732 and 1918, Saint Petersburg was the capital of Imperial Russia. In 1918, the central government bodies moved to Moscow, which is located about 625 kilometres (388 miles) to the south-east.

 

Saint Petersburg is also the cultural capital of Russia. "The Historic Centre of Saint Petersburg and Related Groups of Monuments" constitute a UNESCO World Heritage Site. Saint Petersburg is home to the Hermitage, one of the largest art museums in the world. Many foreign consulates, international corporations, banks and businesses have offices in Saint Petersburg. The multinational Gazprom company has its headquarters in the newly erected Lakhta Center.

Most of the credit here goes to Ian, I stole practically at least half the design elements from him, and he outright built the entire nose after I failed at it for hours. So this is really a co-build, more than anything. Sîana here has 72 kinetic energy weapons (standard guns), four plasma cannon turrets (two guns per turret), and one definitely-not-original particle beam on the bow running the length of the ship (looted from a world the Archive declared off-limits). This is not to mention all her secondary weapons, which I'm too tired to do. Like all Old Coalition ships, she's got technology much more advanced than usual, and is almost self-aware in her system's conduct.

 

Now enjoy this long-ass backstory I made up while I should have been sleeping. Don't read if you're not interested in the 23rd Century theme. Even then, I doubt most of them will read all of it.

-----------------------------------

This ship, like the Îradrakaia, came out of the Hethorîon shipyards a very long time ago. In fact, it was so long ago that Hethorîon was a republic instead of barony, and had a population of two billion instead of one hundred million. Yes folks, this is an Old Coalition ship, only one of two of her class to survive. In fact, she's even in her Old Coalition colors, as she would have appeared before, during, and for quite some time after the Beacon Cataclysm.

 

Sîana was paired with her sister ship, Sîacha, for most of her career on the Thyrendi frontier. Sîacha went on to become the flagship of a Hethorîon fleet in an ancient succession war for the throne of Tarsis, the two ships earned much fame for their daring strategy which eventually won their master the throne. The new Emperor gave Sîana to his most loyal and adept Captain, to serve as the flagship for the new noble house of Sîanô (a name definitely related to the ship). The two sister ships parted ways, until the Thôvis Crusade several millennia later.

 

By this modern time in the Earth year of 1736, Sîana had been called in repeadetly against the heathen Sarthîm barbarians and their allies. The Coalition had seemingly secured most of the territory it set out to take by then, but the Great Foundries remained out of reach and unassailable to the exchausted Tarsin war machine. Sîana was caught up in the initial Sarthîon attack, and quickly isolated as the Imperial fronts collapsed across the entire theatre. While Sîacha and other ships managed to retreat to Imperial space in time to make a stand at the planet of Mysena, Sîana and her crew were not so lucky. They would spend the next four years behind enemy lines, blinded by the destruction of the regional warpspace beacon network, attempting to make their way home. What was worse is that their return went unheralded; by the time they made it back, as civil war erupted over yet another disputed succession and the Sarthîm barbarians continued their counter-attack. It would be another two years until Sîana made it home, where she'd stay for the next five hundred years until being called to battle against the new enemy of Earth.

Ex. NVS # 126 from Schwerin arrived in Almaty in 2004 in the years of the system's slight revival after the 90s. As all other Schweriners, it contained a second cabless twin car. The latter was in service until 2006 and 1027 was the last of the operating multiple-units here. The head car was running through the next years until the arrival of ex-Berliners in 2013.

 

Baytursynov koshesi, Almaty, KZ

Gare SNCF de Bourg-Saint-Maurice 20/01/2018 10h07

This TGV-Duplex of the type Euro-duplex built in the year 2014 with fleet number 4730 is about to depart as TGV 6422 to Paris Gare de Lyon where it will arrive around 15h00 in the afternoon.

 

TGV Duplex

The TGV Duplex is a French high-speed train of the TGV family, manufactured by Alstom, and operated by the French national railway company SNCF. It is unique among TGV trains in that it features bi-level carriages. The Duplex inaugurated the third generation of TGV trainsets. It was specially designed to increase capacity on high-speed lines with saturated traffic. With two seating levels and a seating capacity of 508 passengers, the Duplex increases the passenger capacity. While the TGV Duplex started as a small component of the TGV fleet, it has become one of the system's workhorses.

 

FACTS & FIGURES

Manufacturer: GEC-Alsthom, Alstom

Constructed: 1995–2012

Numbers built:

- 89 trainsets (Duplex), fleetnumbers 201 - 289 (built 1995 - 2006)

- 52 trainsets (Dasye), fleetnumbers 701-720 & 733-749 & 760-772

- 19 trainsets Reseau Duplex, fleetnumbers 601-619 (built 2009-2012)

- 55 TGV 2N2 Euroduplex, fleetnumbers 801-825 & 4701 - 4730 (built 2011 - 2019)

Formation: 10 cars (2 power cars, 8 passenger cars)

Capacity: 508 seats

Train length: 200 m

Maximum speed: 320 km/h

[ Source and more Information: Wikipedia - TGV Duplex ]

 

“APOLLO APPLICATIONS – TECHNOLOGY EXPERIMENTS – MAINTENANCE AND REPAIR TECHNIQUES”

 

As with many other grand Shuttle & Apollo concepts, the Apollo Applications Program (AAP) is yet another that confuses me…along with Apollo “X” and the Apollo Extension System(s) (AES). I initially want to call this an AES configuration.

With that said, per Wikipedia, since it’s easier to find/reference than the random buried, obscure, inaccessible (to peons such as myself) or non-existent documentation that may/may not be out there:

 

“The Apollo Applications Program (AAP) was created as early as 1966 by NASA headquarters to develop science-based human spaceflight missions using hardware developed for the Apollo program. AAP was the ultimate development of a number of official and unofficial Apollo follow-on projects studied at various NASA labs. However, the AAP's ambitious initial plans became an early casualty when the Johnson Administration declined to support it adequately, partly in order to implement its Great Society set of domestic programs while remaining within a $100 billion budget. Thus, Fiscal Year 1967 ultimately allocated $80 million to the AAP, compared to NASA's preliminary estimates of $450 million necessary to fund a full-scale AAP program for that year, with over $1 billion being required for FY 1968. The AAP eventually led to Skylab, which absorbed much of what had been developed under Apollo Applications.

 

Origins

 

NASA management was concerned about losing the 400,000 workers involved in Apollo after landing on the Moon in 1969. A reason Wernher von Braun, head of NASA's Marshall Space Flight Center during the 1960s, advocated for a smaller station after his large one was not built was that he wished to provide his employees with work beyond developing the Saturn rockets, which would be completed relatively early during Project Apollo. NASA set up the Apollo Logistic Support System Office, originally intended to study various ways to modify the Apollo hardware for scientific missions. Initially the AAP office was an offshoot of the Apollo "X" bureau, also known as the Apollo Extension Series. AES was developing technology concepts for mission proposals based on the Saturn IB and Saturn V boosters. These included a crewed lunar base, an Earth-orbiting space station, the so-called Grand Tour of the Outer Solar System, and the original Voyager program of Mars Lander probes.”

 

Above at:

 

en.wikipedia.org/wiki/Apollo_Applications_Program

 

Further, per a diagram within David Shayler’s excellent book, “Apollo: The Lost and Forgotten Missions”, Springer-Praxis, this configuration sort of looks like what’s labeled “EXTENDED APOLLO SYSTEM UTILIZATION STUDY”.

 

So, the untethered Astronaut, in a hybrid Gemini-like space suit, possibly wearing an AMU-Lite, without a single hand-tool, is practicing “maintenance” & “repair” on a "serviceable" engineering/demonstrator module. Maybe it’s just a manual dexterity test?

No signature visible.

On Saturday, October 7, more than 1,700 of Rochester Regional Health’s friends and employees gathered at the Joseph A. Floreano Rochester Riverside Convention Center for the system’s signature celebration.

The old warehouse and barracks on Tern Island in the French Frigate Shoals, Hawaii.

 

Camera: Olympus OM-1

Lens: Olympus OM-System S Zuiko MC Auto-Zoom f/4 35-70mm. Red filter.

Film: Adox HR-50

Developer: Beerenol (Rainier Beer)

Boeing and NASA teams participate in a mission dress rehearsal to prepare for the landing of the Boeing CST-100 Starliner spacecraft in White Sands, New Mexico, Monday, May 23, 2022. Boeing’s Orbital Flight Test-2 (OFT-2) is Starliner’s second uncrewed flight test to the International Space Station as part of NASA's Commercial Crew Program. OFT-2 serves as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Bill Ingalls)

A SpaceX Falcon 9 rocket with the company's Crew Dragon spacecraft onboard is seen as it is rolled out of the horizontal integration facility at Launch Complex 39A as preparations continue for the Demo-1 mission, Feb. 28, 2019 at the Kennedy Space Center in Florida. The Demo-1 mission will be the first launch of a commercially built and operated American spacecraft and space system designed for humans as part of NASA's Commercial Crew Program. The mission, currently targeted for a 2:49am launch on March 2, will serve as an end-to-end test of the system's capabilities Photo Credit: (NASA/Joel Kowsky)

The Space Launch System’s booster is seen a few hours ahead of the second and final qualification motor (QM-2) test, Tuesday, June 28, 2016, at Orbital ATK Propulsion Systems test facilities in Promontory, Utah. During the Space Launch System flight the boosters will provide more than 75 percent of the thrust needed to escape the gravitational pull of the Earth, the first step on NASA’s Journey to Mars. Photo Credit: (NASA/Bill Ingalls)

Cu tren EC 275 METROPOLITAN Praha hlavni nadrazi - Budapest Nyugati p.u.

 

Budapest Nyugati p.u.,

07.08,2023

What do you do when trash is piling up and there's nowhere to put it? You invent teleportation of course! Then you retrofit a fleet of municipal custodial vehicles to power miniaturized teleporters and send them on their way. The original vehicle had its nose lengthened to house the power cells and micro-reactor necessary to power the device, and the whole frame was reworked to bear the weight of the device. The result is a somewhat ungainly vehicle that is notoriously difficult to control.

Although the far-side output location for the teleporter is a closely guarded secret, the rumor-mill places it high above a barren lava plain on the third moon of one of the system's gas giants. Speaking of rumors, gossip and tall tales surround the trash teleporter. There are stories of city workers looking the other way or taking payoffs as organized crime syndicates dispose of evidence and "competition". Although the manufacturers insist that the portals are one-way, city workers insist they have seen "things" coming back through the gateway: from the odd grotesque hand reaching through, to the occasional swarm of flying creatures funneling out of the vortex. There's even whispers that the municipal garage is now inhabited by a shape-shifting beast that made its way through when the teleporter was left on overnight by a careless worker...

A SpaceX Falcon 9 rocket with the company's Crew Dragon spacecraft onboard is seen on the launch pad at Launch Complex 39A as preparations continue for the Demo-1 mission, Friday, March 1, 2019 at the Kennedy Space Center in Florida. The Demo-1 mission launched at 2:49am ET on Saturday, March 2 and was the first launch of a commercially built and operated American spacecraft and space system designed for humans as part of NASA's Commercial Crew Program. The mission will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Joel Kowsky)

Lockheed Martin’s In-space Upgrade Satellite System (LM LINUSS™) is a pair of LM 50™ 12U CubeSats designed to demonstrate how small satellites can serve an essential role in sustaining critical space architectures in any orbit. LM LINUSS was designed to demonstrate how small CubeSats can regularly upgrade satellite constellations to add timely new capabilities and extend spacecraft design lives. The system’s mission is to validate essential maneuvering capabilities for Lockheed Martin’s future space upgrade and servicing missions, as well as to showcase miniaturized Space Domain Awareness capabilities. More info: www.lockheedmartin.com/en-us/products/satellite.html

The Boeing CST-100 Starliner spacecraft jettisons the heat shield as it lands at White Sands Missile Range’s Space Harbor, Wednesday, May 25, 2022, in New Mexico. Boeing’s Orbital Flight Test-2 (OFT-2) is Starliner’s second uncrewed flight test to the International Space Station as part of NASA's Commercial Crew Program. OFT-2 serves as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Bill Ingalls)

A United Launch Alliance Atlas V rocket with Boeing’s CST-100 Starliner spacecraft aboard is seen after being rolled out of the Vertical Integration Facility to the launch pad at Space Launch Complex 41 ahead of the Orbital Flight Test-2 (OFT-2) mission, Wednesday, May 18, 2022 at Cape Canaveral Space Force Station in Florida. Boeing’s Orbital Flight Test-2 will be Starliner’s second uncrewed flight test and will dock to the International Space Station as part of NASA's Commercial Crew Program. The mission, currently targeted for launch at 6:54 p.m. ET on May 19, will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Joel Kowsky)

NASA’s Lucy spacecraft is moved to the horizontal position on a rotation stand inside the Astrotech Space Operations Facility in Titusville, Florida, on Sept. 1, 2021. In view, the high gain antenna and solar arrays have been installed on the Lucy spacecraft. Lucy is scheduled to launch no earlier than Saturday, Oct. 16, on a United Launch Alliance Atlas V 401 rocket from Launch Pad 41 at Cape Canaveral Space Force Station. NASA’s Launch Services Program based at Kennedy Space Center is managing the launch. Over its 12-year primary mission, Lucy will explore a record-breaking number of asteroids, flying by one asteroid in the solar system’s main belt and seven Trojan asteroids. Additionally, Lucy’s path will circle back to Earth three times for gravity assists, making it the first spacecraft ever to return to the vicinity of Earth from the outer solar system. Photo credit: NASA/Glenn Benson

NASA image use policy.

 

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[8] The disease was first identified in December 2019 in Wuhan, the capital of China's Hubei province, and has since spread globally, resulting in the ongoing 2019–20 coronavirus pandemic.[9][10] As of 26 April 2020, more than 2.89 million cases have been reported across 185 countries and territories, resulting in more than 203,000 deaths. More than 822,000 people have recovered.[7]

 

Common symptoms include fever, cough, fatigue, shortness of breath and loss of smell.[5][11][12] While the majority of cases result in mild symptoms, some progress to viral pneumonia, multi-organ failure, or cytokine storm.[13][9][14] More concerning symptoms include difficulty breathing, persistent chest pain, confusion, difficulty waking, and bluish skin.[5] The time from exposure to onset of symptoms is typically around five days but may range from two to fourteen days.[5][15]

 

The virus is primarily spread between people during close contact,[a] often via small droplets produced by coughing,[b] sneezing, or talking.[6][16][18] The droplets usually fall to the ground or onto surfaces rather than remaining in the air over long distances.[6][19][20] People may also become infected by touching a contaminated surface and then touching their face.[6][16] In experimental settings, the virus may survive on surfaces for up to 72 hours.[21][22][23] It is most contagious during the first three days after the onset of symptoms, although spread may be possible before symptoms appear and in later stages of the disease.[24] The standard method of diagnosis is by real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab.[25] Chest CT imaging may also be helpful for diagnosis in individuals where there is a high suspicion of infection based on symptoms and risk factors; however, guidelines do not recommend using it for routine screening.[26][27]

 

Recommended measures to prevent infection include frequent hand washing, maintaining physical distance from others (especially from those with symptoms), covering coughs, and keeping unwashed hands away from the face.[28][29] In addition, the use of a face covering is recommended for those who suspect they have the virus and their caregivers.[30][31] Recommendations for face covering use by the general public vary, with some authorities recommending against their use, some recommending their use, and others requiring their use.[32][31][33] Currently, there is not enough evidence for or against the use of masks (medical or other) in healthy individuals in the wider community.[6] Also masks purchased by the public may impact availability for health care providers.

 

Currently, there is no vaccine or specific antiviral treatment for COVID-19.[6] Management involves the treatment of symptoms, supportive care, isolation, and experimental measures.[34] The World Health Organization (WHO) declared the 2019–20 coronavirus outbreak a Public Health Emergency of International Concern (PHEIC)[35][36] on 30 January 2020 and a pandemic on 11 March 2020.[10] Local transmission of the disease has occurred in most countries across all six WHO regions.[37]

 

File:En.Wikipedia-VideoWiki-Coronavirus disease 2019.webm

Video summary (script)

 

Contents

1Signs and symptoms

2Cause

2.1Transmission

2.2Virology

3Pathophysiology

3.1Immunopathology

4Diagnosis

4.1Pathology

5Prevention

6Management

6.1Medications

6.2Protective equipment

6.3Mechanical ventilation

6.4Acute respiratory distress syndrome

6.5Experimental treatment

6.6Information technology

6.7Psychological support

7Prognosis

7.1Reinfection

8History

9Epidemiology

9.1Infection fatality rate

9.2Sex differences

10Society and culture

10.1Name

10.2Misinformation

10.3Protests

11Other animals

12Research

12.1Vaccine

12.2Medications

12.3Anti-cytokine storm

12.4Passive antibodies

13See also

14Notes

15References

16External links

16.1Health agencies

16.2Directories

16.3Medical journals

Signs and symptoms

Symptom[4]Range

Fever83–99%

Cough59–82%

Loss of Appetite40–84%

Fatigue44–70%

Shortness of breath31–40%

Coughing up sputum28–33%

Loss of smell15[38] to 30%[12][39]

Muscle aches and pains11–35%

Fever is the most common symptom, although some older people and those with other health problems experience fever later in the disease.[4][40] In one study, 44% of people had fever when they presented to the hospital, while 89% went on to develop fever at some point during their hospitalization.[4][41]

 

Other common symptoms include cough, loss of appetite, fatigue, shortness of breath, sputum production, and muscle and joint pains.[4][5][42][43] Symptoms such as nausea, vomiting and diarrhoea have been observed in varying percentages.[44][45][46] Less common symptoms include sneezing, runny nose, or sore throat.[47]

 

More serious symptoms include difficulty breathing, persistent chest pain or pressure, confusion, difficulty waking, and bluish face or lips. Immediate medical attention is advised if these symptoms are present.[5][48]

 

In some, the disease may progress to pneumonia, multi-organ failure, and death.[9][14] In those who develop severe symptoms, time from symptom onset to needing mechanical ventilation is typically eight days.[4] Some cases in China initially presented with only chest tightness and palpitations.[49]

 

Loss of smell was identified as a common symptom of COVID‑19 in March 2020,[12][39] although perhaps not as common as initially reported.[38] A decreased sense of smell and/or disturbances in taste have also been reported.[50] Estimates for loss of smell range from 15%[38] to 30%.[12][39]

 

As is common with infections, there is a delay between the moment a person is first infected and the time he or she develops symptoms. This is called the incubation period. The incubation period for COVID‑19 is typically five to six days but may range from two to 14 days,[51][52] although 97.5% of people who develop symptoms will do so within 11.5 days of infection.[53]

 

A minority of cases do not develop noticeable symptoms at any point in time.[54][55] These asymptomatic carriers tend not to get tested, and their role in transmission is not yet fully known.[56][57] However, preliminary evidence suggests they may contribute to the spread of the disease.[58][59] In March 2020, the Korea Centers for Disease Control and Prevention (KCDC) reported that 20% of confirmed cases remained asymptomatic during their hospital stay.[59][60]

 

A number of neurological symptoms has been reported including seizures, stroke, encephalitis and Guillain-Barre syndrome.[61] Cardiovascular related complications may include heart failure, irregular electrical activity, blood clots, and heart inflammation.[62]

 

Cause

See also: Severe acute respiratory syndrome coronavirus 2

Transmission

Cough/sneeze droplets visualised in dark background using Tyndall scattering

Respiratory droplets produced when a man is sneezing visualised using Tyndall scattering

File:COVID19 in numbers- R0, the case fatality rate and why we need to flatten the curve.webm

A video discussing the basic reproduction number and case fatality rate in the context of the pandemic

Some details about how the disease is spread are still being determined.[16][18] The WHO and the U.S. Centers for Disease Control and Prevention (CDC) say it is primarily spread during close contact and by small droplets produced when people cough, sneeze or talk;[6][16] with close contact being within approximately 1–2 m (3–7 ft).[6][63] Both sputum and saliva can carry large viral loads.[64] Loud talking releases more droplets than normal talking.[65] A study in Singapore found that an uncovered cough can lead to droplets travelling up to 4.5 metres (15 feet).[66] An article published in March 2020 argued that advice on droplet distance might be based on 1930s research which ignored the effects of warm moist exhaled air surrounding the droplets and that an uncovered cough or sneeze can travel up to 8.2 metres (27 feet).[17]

  

Respiratory droplets may also be produced while breathing out, including when talking. Though the virus is not generally airborne,[6][67] the National Academy of Sciences has suggested that bioaerosol transmission may be possible.[68] In one study cited, air collectors positioned in the hallway outside of people's rooms yielded samples positive for viral RNA but finding infectious virus has proven elusive.[68] The droplets can land in the mouths or noses of people who are nearby or possibly be inhaled into the lungs.[16] Some medical procedures such as intubation and cardiopulmonary resuscitation (CPR) may cause respiratory secretions to be aerosolised and thus result in an airborne spread.[67] Initial studies suggested a doubling time of the number of infected persons of 6–7 days and a basic reproduction number (R0 ) of 2.2–2.7, but a study published on April 7, 2020, calculated a much higher median R0 value of 5.7 in Wuhan.[69]

 

It may also spread when one touches a contaminated surface, known as fomite transmission, and then touches one's eyes, nose or mouth.[6] While there are concerns it may spread via faeces, this risk is believed to be low.[6][16]

 

The virus is most contagious when people are symptomatic; though spread is may be possible before symptoms emerge and from those who never develop symptoms.[6][70] A portion of individuals with coronavirus lack symptoms.[71] The European Centre for Disease Prevention and Control (ECDC) says while it is not entirely clear how easily the disease spreads, one person generally infects two or three others.[18]

 

The virus survives for hours to days on surfaces.[6][18] Specifically, the virus was found to be detectable for one day on cardboard, for up to three days on plastic (polypropylene) and stainless steel (AISI 304), and for up to four hours on 99% copper.[21][23] This, however, varies depending on the humidity and temperature.[72][73] Surfaces may be decontaminated with many solutions (with one minute of exposure to the product achieving a 4 or more log reduction (99.99% reduction)), including 78–95% ethanol (alcohol used in spirits), 70–100% 2-propanol (isopropyl alcohol), the combination of 45% 2-propanol with 30% 1-propanol, 0.21% sodium hypochlorite (bleach), 0.5% hydrogen peroxide, or 0.23–7.5% povidone-iodine. Soap and detergent are also effective if correctly used; soap products degrade the virus' fatty protective layer, deactivating it, as well as freeing them from the skin and other surfaces.[74] Other solutions, such as benzalkonium chloride and chlorhexidine gluconate (a surgical disinfectant), are less effective.[75]

 

In a Hong Kong study, saliva samples were taken a median of two days after the start of hospitalization. In five of six patients, the first sample showed the highest viral load, and the sixth patient showed the highest viral load on the second day tested.[64]

 

Virology

Main article: Severe acute respiratory syndrome coronavirus 2

 

Illustration of SARSr-CoV virion

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus, first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan.[76] All features of the novel SARS-CoV-2 virus occur in related coronaviruses in nature.[77] Outside the human body, the virus is killed by household soap, which bursts its protective bubble.[26]

 

SARS-CoV-2 is closely related to the original SARS-CoV.[78] It is thought to have a zoonotic origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus, in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13).[47] In February 2020, Chinese researchers found that there is only one amino acid difference in the binding domain of the S protein between the coronaviruses from pangolins and those from humans; however, whole-genome comparison to date found that at most 92% of genetic material was shared between pangolin coronavirus and SARS-CoV-2, which is insufficient to prove pangolins to be the intermediate host.[79]

 

Pathophysiology

The lungs are the organs most affected by COVID‑19 because the virus accesses host cells via the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant in type II alveolar cells of the lungs. The virus uses a special surface glycoprotein called a "spike" (peplomer) to connect to ACE2 and enter the host cell.[80] The density of ACE2 in each tissue correlates with the severity of the disease in that tissue and some have suggested that decreasing ACE2 activity might be protective,[81][82] though another view is that increasing ACE2 using angiotensin II receptor blocker medications could be protective and these hypotheses need to be tested.[83] As the alveolar disease progresses, respiratory failure might develop and death may follow.[82]

 

The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium[84] as well as endothelial cells and enterocytes of the small intestine.[85]

 

ACE2 is present in the brain, and there is growing evidence of neurological manifestations in people with COVID‑19. It is not certain if the virus can directly infect the brain by crossing the barriers that separate the circulation of the brain and the general circulation. Other coronaviruses are able to infect the brain via a synaptic route to the respiratory centre in the medulla, through mechanoreceptors like pulmonary stretch receptors and chemoreceptors (primarily central chemoreceptors) within the lungs.[medical citation needed] It is possible that dysfunction within the respiratory centre further worsens the ARDS seen in COVID‑19 patients. Common neurological presentations include a loss of smell, headaches, nausea, and vomiting. Encephalopathy has been noted to occur in some patients (and confirmed with imaging), with some reports of detection of the virus after cerebrospinal fluid assays although the presence of oligoclonal bands seems to be a common denominator in these patients.[86]

 

The virus can cause acute myocardial injury and chronic damage to the cardiovascular system.[87] An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China,[88] and is more frequent in severe disease.[89] Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart.[87] ACE2 receptors are highly expressed in the heart and are involved in heart function.[87][90] A high incidence of thrombosis (31%) and venous thromboembolism (25%) have been found in ICU patients with COVID‑19 infections and may be related to poor prognosis.[91][92] Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels) are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolisms, and ischaemic events within the brain have been noted as complications leading to death in patients infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses within the body, constriction of blood vessels within the pulmonary circulation has also been posited as a mechanism in which oxygenation decreases alongside with the presentation of viral pneumonia.[93]

 

Another common cause of death is complications related to the kidneys[93]—SARS-CoV-2 directly infects kidney cells, as confirmed in post-mortem studies. Acute kidney injury is a common complication and cause of death; this is more significant in patients with already compromised kidney function, especially in people with pre-existing chronic conditions such as hypertension and diabetes which specifically cause nephropathy in the long run.[94]

 

Autopsies of people who died of COVID‑19 have found diffuse alveolar damage (DAD), and lymphocyte-containing inflammatory infiltrates within the lung.[95]

 

Immunopathology

Although SARS-COV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, patients with severe COVID‑19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL-2, IL-7, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-α (MIP-1α), and tumour necrosis factor-α (TNF-α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.[96]

 

Additionally, people with COVID‑19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.[97]

 

Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T-cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in COVID‑19 patients.[98] Lymphocytic infiltrates have also been reported at autopsy.[95]

 

Diagnosis

Main article: COVID-19 testing

 

Demonstration of a nasopharyngeal swab for COVID-19 testing

 

CDC rRT-PCR test kit for COVID-19[99]

The WHO has published several testing protocols for the disease.[100] The standard method of testing is real-time reverse transcription polymerase chain reaction (rRT-PCR).[101] The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used.[25][102] Results are generally available within a few hours to two days.[103][104] Blood tests can be used, but these require two blood samples taken two weeks apart, and the results have little immediate value.[105] Chinese scientists were able to isolate a strain of the coronavirus and publish the genetic sequence so laboratories across the world could independently develop polymerase chain reaction (PCR) tests to detect infection by the virus.[9][106][107] As of 4 April 2020, antibody tests (which may detect active infections and whether a person had been infected in the past) were in development, but not yet widely used.[108][109][110] The Chinese experience with testing has shown the accuracy is only 60 to 70%.[111] The FDA in the United States approved the first point-of-care test on 21 March 2020 for use at the end of that month.[112]

 

Diagnostic guidelines released by Zhongnan Hospital of Wuhan University suggested methods for detecting infections based upon clinical features and epidemiological risk. These involved identifying people who had at least two of the following symptoms in addition to a history of travel to Wuhan or contact with other infected people: fever, imaging features of pneumonia, normal or reduced white blood cell count, or reduced lymphocyte count.[113]

 

A study asked hospitalised COVID‑19 patients to cough into a sterile container, thus producing a saliva sample, and detected the virus in eleven of twelve patients using RT-PCR. This technique has the potential of being quicker than a swab and involving less risk to health care workers (collection at home or in the car).[64]

 

Along with laboratory testing, chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening.[26][27] Bilateral multilobar ground-glass opacities with a peripheral, asymmetric, and posterior distribution are common in early infection.[26] Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses.[26][114]

 

In late 2019, WHO assigned the emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID‑19 without lab-confirmed SARS-CoV-2 infection.[115]

  

Typical CT imaging findings

 

CT imaging of rapid progression stage

Pathology

Few data are available about microscopic lesions and the pathophysiology of COVID‑19.[116][117] The main pathological findings at autopsy are:

 

Macroscopy: pleurisy, pericarditis, lung consolidation and pulmonary oedema

Four types of severity of viral pneumonia can be observed:

minor pneumonia: minor serous exudation, minor fibrin exudation

mild pneumonia: pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation

severe pneumonia: diffuse alveolar damage (DAD) with diffuse alveolar exudates. DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxemia.

healing pneumonia: organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis

plasmocytosis in BAL[118]

Blood: disseminated intravascular coagulation (DIC);[119] leukoerythroblastic reaction[120]

Liver: microvesicular steatosis

Prevention

See also: 2019–20 coronavirus pandemic § Prevention, flatten the curve, and workplace hazard controls for COVID-19

 

Progressively stronger mitigation efforts to reduce the number of active cases at any given time—known as "flattening the curve"—allows healthcare services to better manage the same volume of patients.[121][122][123] Likewise, progressively greater increases in healthcare capacity—called raising the line—such as by increasing bed count, personnel, and equipment, helps to meet increased demand.[124]

 

Mitigation attempts that are inadequate in strictness or duration—such as premature relaxation of distancing rules or stay-at-home orders—can allow a resurgence after the initial surge and mitigation.[122][125]

Preventive measures to reduce the chances of infection include staying at home, avoiding crowded places, keeping distance from others, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.[126][127][128] The CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available.[126] Proper hand hygiene after any cough or sneeze is encouraged.[126] The CDC has recommended the use of cloth face coverings in public settings where other social distancing measures are difficult to maintain, in part to limit transmission by asymptomatic individuals.[129] The U.S. National Institutes of Health guidelines do not recommend any medication for prevention of COVID‑19, before or after exposure to the SARS-CoV-2 virus, outside of the setting of a clinical trial.[130]

 

Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel, and cancelling large public gatherings.[131] Distancing guidelines also include that people stay at least 6 feet (1.8 m) apart.[132] There is no medication known to be effective at preventing COVID‑19.[133] After the implementation of social distancing and stay-at-home orders, many regions have been able to sustain an effective transmission rate ("Rt") of less than one, meaning the disease is in remission in those areas.[134]

 

As a vaccine is not expected until 2021 at the earliest,[135] a key part of managing COVID‑19 is trying to decrease the epidemic peak, known as "flattening the curve".[122] This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until effective treatments or a vaccine become available.[122][125]

 

According to the WHO, the use of masks is recommended only if a person is coughing or sneezing or when one is taking care of someone with a suspected infection.[136] For the European Centre for Disease Prevention and Control (ECDC) face masks "... could be considered especially when visiting busy closed spaces ..." but "... only as a complementary measure ..."[137] Several countries have recommended that healthy individuals wear face masks or cloth face coverings (like scarves or bandanas) at least in certain public settings, including China,[138] Hong Kong,[139] Spain,[140] Italy (Lombardy region),[141] and the United States.[129]

 

Those diagnosed with COVID‑19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.[30][142] The CDC also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose, coughing or sneezing. It further recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available.[126]

 

For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis". Glycerol is added as a humectant.[143]

  

Prevention efforts are multiplicative, with effects far beyond that of a single spread. Each avoided case leads to more avoided cases down the line, which in turn can stop the outbreak in its tracks.

 

File:COVID19 W ENG.ogv

Handwashing instructions

Management

People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.[144][145][146] The CDC recommends that those who suspect they carry the virus wear a simple face mask.[30] Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.[41][147] Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity.[148] Supportive treatments may be useful in those with mild symptoms at the early stage of infection.[149]

 

The WHO, the Chinese National Health Commission, and the United States' National Institutes of Health have published recommendations for taking care of people who are hospitalised with COVID‑19.[130][150][151] Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC.[152][153]

 

Medications

See also: Coronavirus disease 2019 § Research

As of April 2020, there is no specific treatment for COVID‑19.[6][133] Research is, however, ongoing. For symptoms, some medical professionals recommend paracetamol (acetaminophen) over ibuprofen for first-line use.[154][155][156] The WHO and NIH do not oppose the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen for symptoms,[130][157] and the FDA says currently there is no evidence that NSAIDs worsen COVID‑19 symptoms.[158]

 

While theoretical concerns have been raised about ACE inhibitors and angiotensin receptor blockers, as of 19 March 2020, these are not sufficient to justify stopping these medications.[130][159][160][161] Steroids, such as methylprednisolone, are not recommended unless the disease is complicated by acute respiratory distress syndrome.[162][163]

 

Medications to prevent blood clotting have been suggested for treatment,[91] and anticoagulant therapy with low molecular weight heparin appears to be associated with better outcomes in severe COVID‐19 showing signs of coagulopathy (elevated D-dimer).[164]

 

Protective equipment

See also: COVID-19 related shortages

 

The CDC recommends four steps to putting on personal protective equipment (PPE).[165]

Precautions must be taken to minimise the risk of virus transmission, especially in healthcare settings when performing procedures that can generate aerosols, such as intubation or hand ventilation.[166] For healthcare professionals caring for people with COVID‑19, the CDC recommends placing the person in an Airborne Infection Isolation Room (AIIR) in addition to using standard precautions, contact precautions, and airborne precautions.[167]

 

The CDC outlines the guidelines for the use of personal protective equipment (PPE) during the pandemic. The recommended gear is a PPE gown, respirator or facemask, eye protection, and medical gloves.[168][169]

 

When available, respirators (instead of facemasks) are preferred.[170] N95 respirators are approved for industrial settings but the FDA has authorised the masks for use under an Emergency Use Authorisation (EUA). They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses.[171] When masks are not available, the CDC recommends using face shields or, as a last resort, homemade masks.[172]

 

Mechanical ventilation

Most cases of COVID‑19 are not severe enough to require mechanical ventilation or alternatives, but a percentage of cases are.[173][174] The type of respiratory support for individuals with COVID‑19 related respiratory failure is being actively studied for people in the hospital, with some evidence that intubation can be avoided with a high flow nasal cannula or bi-level positive airway pressure.[175] Whether either of these two leads to the same benefit for people who are critically ill is not known.[176] Some doctors prefer staying with invasive mechanical ventilation when available because this technique limits the spread of aerosol particles compared to a high flow nasal cannula.[173]

 

Severe cases are most common in older adults (those older than 60 years,[173] and especially those older than 80 years).[177] Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID‑19 cases severe enough to require hospitalisation.[178] This limited capacity is a significant driver behind calls to flatten the curve.[178] One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died.[41] In China, approximately 30% of people in hospital with COVID‑19 are eventually admitted to ICU.[4]

 

Acute respiratory distress syndrome

Main article: Acute respiratory distress syndrome

Mechanical ventilation becomes more complex as acute respiratory distress syndrome (ARDS) develops in COVID‑19 and oxygenation becomes increasingly difficult.[179] Ventilators capable of pressure control modes and high PEEP[180] are needed to maximise oxygen delivery while minimising the risk of ventilator-associated lung injury and pneumothorax.[181] High PEEP may not be available on older ventilators.

 

Options for ARDS[179]

TherapyRecommendations

High-flow nasal oxygenFor SpO2 <93%. May prevent the need for intubation and ventilation

Tidal volume6mL per kg and can be reduced to 4mL/kg

Plateau airway pressureKeep below 30 cmH2O if possible (high respiratory rate (35 per minute) may be required)

Positive end-expiratory pressureModerate to high levels

Prone positioningFor worsening oxygenation

Fluid managementGoal is a negative balance of 0.5–1.0L per day

AntibioticsFor secondary bacterial infections

GlucocorticoidsNot recommended

Experimental treatment

See also: § Research

Research into potential treatments started in January 2020,[182] and several antiviral drugs are in clinical trials.[183][184] Remdesivir appears to be the most promising.[133] Although new medications may take until 2021 to develop,[185] several of the medications being tested are already approved for other uses or are already in advanced testing.[186] Antiviral medication may be tried in people with severe disease.[144] The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments.[187]

 

The FDA has granted temporary authorisation to convalescent plasma as an experimental treatment in cases where the person's life is seriously or immediately threatened. It has not undergone the clinical studies needed to show it is safe and effective for the disease.[188][189][190]

 

Information technology

See also: Contact tracing and Government by algorithm

In February 2020, China launched a mobile app to deal with the disease outbreak.[191] Users are asked to enter their name and ID number. The app can detect 'close contact' using surveillance data and therefore a potential risk of infection. Every user can also check the status of three other users. If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials.[192]

 

Big data analytics on cellphone data, facial recognition technology, mobile phone tracking, and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan, and Singapore.[193][194] In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus. The measure was taken to enforce quarantine and protect those who may come into contact with infected citizens.[195] Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, to research and prevent the spread of the virus.[196] Russia deployed facial recognition technology to detect quarantine breakers.[197] Italian regional health commissioner Giulio Gallera said he has been informed by mobile phone operators that "40% of people are continuing to move around anyway".[198] German government conducted a 48 hours weekend hackathon with more than 42.000 participants.[199][200] Two million people in the UK used an app developed in March 2020 by King's College London and Zoe to track people with COVID‑19 symptoms.[201] Also, the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus.[202]

 

Psychological support

See also: Mental health during the 2019–20 coronavirus pandemic

Individuals may experience distress from quarantine, travel restrictions, side effects of treatment, or fear of the infection itself. To address these concerns, the National Health Commission of China published a national guideline for psychological crisis intervention on 27 January 2020.[203][204]

 

The Lancet published a 14-page call for action focusing on the UK and stated conditions were such that a range of mental health issues was likely to become more common. BBC quoted Rory O'Connor in saying, "Increased social isolation, loneliness, health anxiety, stress and an economic downturn are a perfect storm to harm people's mental health and wellbeing."[205][206]

 

Prognosis

Question book-new.svg

This article relies too much on references to primary sources. Please improve this by adding secondary or tertiary sources. (March 2020) (Learn how and when to remove this template message)

The severity of diagnosed cases in China

The severity of diagnosed COVID-19 cases in China[207]

Case fatality rates for COVID-19 by age by country.

Case fatality rates by age group:

China, as of 11 February 2020[208]

South Korea, as of 15 April 2020[209]

Spain, as of 24 April 2020[210]

Italy, as of 23 April 2020[211]

Case fatality rate depending on other health problems

Case fatality rate in China depending on other health problems. Data through 11 February 2020.[208]

Case fatality rate by country and number of cases

The number of deaths vs total cases by country and approximate case fatality rate[212]

The severity of COVID‑19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks.[47]

 

Children make up a small proportion of reported cases, with about 1% of cases being under 10 years, and 4% aged 10-19 years.[22] They are likely to have milder symptoms and a lower chance of severe disease than adults; in those younger than 50 years, the risk of death is less than 0.5%, while in those older than 70 it is more than 8%.[213][214][215] Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.[216][217] In China, children acquired infections mainly through close contact with their parents or other family members who lived in Wuhan or had traveled there.[213]

 

In some people, COVID‑19 may affect the lungs causing pneumonia. In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock, or multi-organ failure.[218][219] Complications associated with COVID‑19 include sepsis, abnormal clotting, and damage to the heart, kidneys, and liver. Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group.[220] Approximately 20-30% of people who present with COVID‑19 demonstrate elevated liver enzymes (transaminases).[133] Liver injury as shown by blood markers of liver damage is frequently seen in severe cases.[221]

 

Some studies have found that the neutrophil to lymphocyte ratio (NLR) may be helpful in early screening for severe illness.[222]

 

Most of those who die of COVID‑19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease.[223] The Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available for review, 97.2% of sampled patients had at least one comorbidity with the average patient having 2.7 diseases.[224] According to the same report, the median time between the onset of symptoms and death was ten days, with five being spent hospitalised. However, patients transferred to an ICU had a median time of seven days between hospitalisation and death.[224] In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.[225] In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.[226] Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs. Viral cytopathic changes were observed in the pneumocytes. The lung picture resembled acute respiratory distress syndrome (ARDS).[47] In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.[49] According to March data from the United States, 89% of those hospitalised had preexisting conditions.[227]

 

The availability of medical resources and the socioeconomics of a region may also affect mortality.[228] Estimates of the mortality from the condition vary because of those regional differences,[229] but also because of methodological difficulties. The under-counting of mild cases can cause the mortality rate to be overestimated.[230] However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated.[231][232] Smokers were 1.4 times more likely to have severe symptoms of COVID‑19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.[233]

 

Concerns have been raised about long-term sequelae of the disease. The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.[234] This may also lead to post-intensive care syndrome following recovery.[235]

 

Case fatality rates (%) by age and country

Age0–910–1920–2930–3940–4950–5960–6970–7980-8990+

China as of 11 February[208]0.00.20.20.20.41.33.68.014.8

Denmark as of 25 April[236]0.24.515.524.940.7

Italy as of 23 April[211]0.20.00.10.40.92.610.024.930.826.1

Netherlands as of 17 April[237]0.00.30.10.20.51.57.623.230.029.3

Portugal as of 24 April[238]0.00.00.00.00.30.62.88.516.5

S. Korea as of 15 April[209]0.00.00.00.10.20.72.59.722.2

Spain as of 24 April[210]0.30.40.30.30.61.34.413.220.320.1

Switzerland as of 25 April[239]0.90.00.00.10.00.52.710.124.0

Case fatality rates (%) by age in the United States

Age0–1920–4445–5455–6465–7475–8485+

United States as of 16 March[240]0.00.1–0.20.5–0.81.4–2.62.7–4.94.3–10.510.4–27.3

Note: The lower bound includes all cases. The upper bound excludes cases that were missing data.

Estimate of infection fatality rates and probability of severe disease course (%) by age based on cases from China[241]

0–910–1920–2930–3940–4950–5960–6970–7980+

Severe disease0.0

(0.0–0.0)0.04

(0.02–0.08)1.0

(0.62–2.1)3.4

(2.0–7.0)4.3

(2.5–8.7)8.2

(4.9–17)11

(7.0–24)17

(9.9–34)18

(11–38)

Death0.0016

(0.00016–0.025)0.0070

(0.0015–0.050)0.031

(0.014–0.092)0.084

(0.041–0.19)0.16

(0.076–0.32)0.60

(0.34–1.3)1.9

(1.1–3.9)4.3

(2.5–8.4)7.8

(3.8–13)

Total infection fatality rate is estimated to be 0.66% (0.39–1.3). Infection fatality rate is fatality per all infected individuals, regardless of whether they were diagnosed or had any symptoms. Numbers in parentheses are 95% credible intervals for the estimates.

Reinfection

As of March 2020, it was unknown if past infection provides effective and long-term immunity in people who recover from the disease.[242] Immunity is seen as likely, based on the behaviour of other coronaviruses,[243] but cases in which recovery from COVID‑19 have been followed by positive tests for coronavirus at a later date have been reported.[244][245][246][247] These cases are believed to be worsening of a lingering infection rather than re-infection.[247]

 

History

Main article: Timeline of the 2019–20 coronavirus pandemic

The virus is thought to be natural and has an animal origin,[77] through spillover infection.[248] The actual origin is unknown, but by December 2019 the spread of infection was almost entirely driven by human-to-human transmission.[208][249] A study of the first 41 cases of confirmed COVID‑19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.[250][251][252] Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.[253] Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020.[254][255]

 

Epidemiology

Main article: 2019–20 coronavirus pandemic

Several measures are commonly used to quantify mortality.[256] These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health.[257]

 

The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is 7.0% (203,044/2,899,830) as of 26 April 2020.[7] The number varies by region.[258]

 

Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease. These statistics are not time-bound and follow a specific population from infection through case resolution. Many academics have attempted to calculate these numbers for specific populations.[259]

  

Total confirmed cases over time

 

Total deaths over time

 

Total confirmed cases of COVID‑19 per million people, 10 April 2020[260]

 

Total confirmed deaths due to COVID‑19 per million people, 10 April 2020[261]

Infection fatality rate

Our World in Data states that as of March 25, 2020, the infection fatality rate (IFR) cannot be accurately calculated.[262] In February, the World Health Organization estimated the IFR at 0.94%, with a confidence interval between 0.37 percent to 2.9 percent.[263] The University of Oxford Centre for Evidence-Based Medicine (CEBM) estimated a global CFR of 0.72 percent and IFR of 0.1 percent to 0.36 percent.[264] According to CEBM, random antibody testing in Germany suggested an IFR of 0.37 percent there.[264] Firm lower limits to local infection fatality rates were established, such as in Bergamo province, where 0.57% of the population has died, leading to a minimum IFR of 0.57% in the province. This population fatality rate (PFR) minimum increases as more people get infected and run through their disease.[265][266] Similarly, as of April 22 in the New York City area, there were 15,411 deaths confirmed from COVID-19, and 19,200 excess deaths.[267] Very recently, the first results of antibody testing have come in, but there are no valid scientific reports based on them available yet. A Bloomberg Opinion piece provides a survey.[268][269]

 

Sex differences

Main article: Gendered impact of the 2019–20 coronavirus pandemic

The impact of the pandemic and its mortality rate are different for men and women.[270] Mortality is higher in men in studies conducted in China and Italy.[271][272][273] The highest risk for men is in their 50s, with the gap between men and women closing only at 90.[273] In China, the death rate was 2.8 percent for men and 1.7 percent for women.[273] The exact reasons for this sex-difference are not known, but genetic and behavioural factors could be a reason.[270] Sex-based immunological differences, a lower prevalence of smoking in women, and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.[273] In Europe, of those infected with COVID‑19, 57% were men; of those infected with COVID‑19 who also died, 72% were men.[274] As of April 2020, the U.S. government is not tracking sex-related data of COVID‑19 infections.[275] Research has shown that viral illnesses like Ebola, HIV, influenza, and SARS affect men and women differently.[275] A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.[276] School closures, lockdowns, and reduced access to healthcare following the 2019–20 coronavirus pandemic may differentially affect the genders and possibly exaggerate existing gender disparity.[270][277]

 

Society and culture

Name

During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus",[278][279][280] with the disease sometimes called "Wuhan pneumonia".[281][282] In the past, many diseases have been named after geographical locations, such as the Spanish flu,[283] Middle East Respiratory Syndrome, and Zika virus.[284]

 

In January 2020, the World Health Organisation recommended 2019-nCov[285] and 2019-nCoV acute respiratory disease[286] as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations (e.g. Wuhan, China), animal species or groups of people in disease and virus names to prevent social stigma.[287][288][289]

 

The official names COVID‑19 and SARS-CoV-2 were issued by the WHO on 11 February 2020.[290] WHO chief Tedros Adhanom Ghebreyesus explained: CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019).[291] The WHO additionally uses "the COVID‑19 virus" and "the virus responsible for COVID‑19" in public communications.[290] Both the disease and virus are commonly referred to as "coronavirus" in the media and public discourse.

 

Misinformation

Main article: Misinformation related to the 2019–20 coronavirus pandemic

After the initial outbreak of COVID‑19, conspiracy theories, misinformation, and disinformation emerged regarding the origin, scale, prevention, treatment, and other aspects of the disease and rapidly spread online.[292][293][294][295]

 

Protests

Beginning April 17, 2020, news media began reporting on a wave of demonstrations protesting against state-mandated quarantine restrictions in in Michigan, Ohio, and Kentucky.[296][297]

 

Other animals

Humans appear to be capable of spreading the virus to some other animals. A domestic cat in Liège, Belgium, tested positive after it started showing symptoms (diarrhoea, vomiting, shortness of breath) a week later than its owner, who was also positive.[298] Tigers at the Bronx Zoo in New York, United States, tested positive for the virus and showed symptoms of COVID‑19, including a dry cough and loss of appetite.[299]

 

A study on domesticated animals inoculated with the virus found that cats and ferrets appear to be "highly susceptible" to the disease, while dogs appear to be less susceptible, with lower levels of viral replication. The study failed to find evidence of viral replication in pigs, ducks, and chickens.[300]

 

Research

Main article: COVID-19 drug development

No medication or vaccine is approved to treat the disease.[186] International research on vaccines and medicines in COVID‑19 is underway by government organisations, academic groups, and industry researchers.[301][302] In March, the World Health Organisation initiated the "SOLIDARITY Trial" to assess the treatment effects of four existing antiviral compounds with the most promise of efficacy.[303]

 

Vaccine

Main article: COVID-19 vaccine

There is no available vaccine, but various agencies are actively developing vaccine candidates. Previous work on SARS-CoV is being used because both SARS-CoV and SARS-CoV-2 use the ACE2 receptor to enter human cells.[304] Three vaccination strategies are being investigated. First, researchers aim to build a whole virus vaccine. The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID‑19. A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus. In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor. A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination). Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.[305]

 

On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle, United States. The vaccine contains a harmless genetic code copied from the virus that causes the disease.[306]

 

Antibody-dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.[307]

 

Medications

Main article: COVID-19 drug repurposing research

At least 29 phase II–IV efficacy trials in COVID‑19 were concluded in March 2020 or scheduled to provide results in April from hospitals in China.[308][309] There are more than 300 active clinical trials underway as of April 2020.[133] Seven trials were evaluating already approved treatments, including four studies on hydroxychloroquine or chloroquine.[309] Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.[308][309] Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2.[309]

 

The COVID‑19 Clinical Research Coalition has goals to 1) facilitate rapid reviews of clinical trial proposals by ethics committees and national regulatory agencies, 2) fast-track approvals for the candidate therapeutic compounds, 3) ensure standardised and rapid analysis of emerging efficacy and safety data and 4) facilitate sharing of clinical trial outcomes before publication.[310][311]

 

Several existing medications are being evaluated for the treatment of COVID‑19,[186] including remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and lopinavir/ritonavir combined with interferon beta.[303][312] There is tentative evidence for efficacy by remdesivir, as of March 2020.[313][314] Clinical improvement was observed in patients treated with compassionate-use remdesivir.[315] Remdesivir inhibits SARS-CoV-2 in vitro.[316] Phase III clinical trials are underway in the U.S., China, and Italy.[186][308][317]

 

In 2020, a trial found that lopinavir/ritonavir was ineffective in the treatment of severe illness.[318] Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.[316]

 

There are mixed results as of 3 April 2020 as to the effectiveness of hydroxychloroquine as a treatment for COVID‑19, with some studies showing little or no improvement.[319][320] The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.[133]

 

Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID‑19 treatment.[133]

 

Anti-cytokine storm

Cytokine release syndrome (CRS) can be a complication in the later stages of severe COVID‑19. There is preliminary evidence that hydroxychloroquine may have anti-cytokine storm properties.[321]

 

Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.[322][323] It is undergoing a phase 2 non-randomised trial at the national level in Italy after showing positive results in people with severe disease.[324][325] Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.[326][327][328] The interleukin-6 receptor antagonist was approved by the FDA to undergo a phase III clinical trial assessing the medication's impact on COVID‑19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.[329] To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS. Prophylactic tocilizumab has been shown to increase serum IL-6 levels by saturating the IL-6R, driving IL-6 across the blood-brain barrier, and exacerbating neurotoxicity while having no impact on the incidence of CRS.[330]

 

Lenzilumab, an anti-GM-CSF monoclonal antibody, is protective in murine models for CAR T cell-induced CRS and neurotoxicity and is a viable therapeutic option due to the observed increase of pathogenic GM-CSF secreting T-cells in hospitalised patients with COVID‑19.[331]

 

The Feinstein Institute of Northwell Health announced in March a study on "a human antibody that may prevent the activity" of IL-6.[332]

 

Passive antibodies

Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID‑19 to people who need them is being investigated as a non-vaccine method of passive immunisation.[333] This strategy was tried for SARS with inconclusive results.[333] Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2. Other mechanisms, however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.[333] Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.[333] Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.[334]

  

en.wikipedia.org/wiki/Coronavirus_disease_2019

On Saturday, October 7, more than 1,700 of Rochester Regional Health’s friends and employees gathered at the Joseph A. Floreano Rochester Riverside Convention Center for the system’s signature celebration.

The Metropolitan Transportation Authority (MTA) released the first look at its newest state-of-the-art subway cars in production, the R211 class, which is planned for service on the subway system’s lettered routes and the Staten Island Railway.

 

The MTA Board approved the $1.4 billion contract award of 535 R211 cars to Kawasaki Rail Car Inc. in 2018 and the delivery of the first test cars is scheduled for later this year.

After shooting the train at I190 I headed north toward Holden where the line quickly takes on decidedly more rural and old time feel. The scene with an original ex B&M depot is one of the signatures on the line and even with the "wrong light" I was still pleased with the result.

 

A sucker for history, I'll never pass up a shot that includes classic "props" from a line's past.

 

And as for history, how about a little courtesy of the Holden Historical Society?

 

In 1869, the Boston, Barre and Gardner Railroad (BB&G) commenced construction of a railroad from Worcester (at Barber), through Holden, to Gardner. This 26-mile line, which cost 1.2 million dollars to build, opened in 1871. It was extended 10 miles to Winchendon in January, 1874 and later that same year the company leased the Monadnock Railroad north another 16 miles to Peterborough, New Hampshire. The BB&G thus attained a total length of 52 miles.

 

Beset by financial reversals, the Monadnock lease was surrendered to the Cheshire Railroad in 1880. The BB&G was leased itself to the Fitchburg Railroad in 1884. The following year it was merged into the Fitchburg and became that road's Worcester Division. In 1900 the Fitchburg was leased and soon thereafter merged into the Boston & Maine Railroad (B&M), becoming the B&M's Fitchburg Division. As a part of the B&M system's Fitchburg Division the line through Holden was referred to at different times by various names including the Worcester & Contoocook (N.H.) Branch, the Worcester & Hillsboro (N.H.) Branch, the Peterboro (N.H.) Branch, and finally after the line was severed north o f Gardner, as the Worcester Branch of the Fitchburg Division. At Worcester, the line joined the B&M Portland Division's "Worcester Main Line" at Barber.

 

The original 52-mile BB&G line through Holden remained under B&M control for 73 years. In 1974, the line was bought by the Providence and Worcester Railroad (P&W). The last B&M freight left Holden for Worcester in January 1974 and the P&W operated its first train over the line on February 2, 1974.

 

At various times, passenger stops existed at Chaffins, Dawson, Holden, Jefferson, and at North Woods. Holden and Jefferson were small country depots, while the others were flag stops with small shelters. Only two station structures remain: the Holden depot in its original location and the Jefferson depot which was moved in 1975 to a site next to the Wong Dynasty Chinese Restaurant on Reservoir Street.

 

In 1878 there were four round trip passenger trains between Worcester and Winchendon. This increased to six round trips at the turn of the century. Under B&M ownership, the old BB&G line became part of a rather unlikely through passenger route from Worcester to Concord, NH. This service ended after the floods of 1936 severed the line north of Peterboro. However, a round trip passenger local from Worcester to Peterboro would survive another 17 years, handling passengers and mail. In its last years, it acquired a certain degree of fame and became known as the "Peterboro Local" or the "Blueberry Special." By the early 1950s the B&M was hemorrhaging financially from passenger train losses and was given permission to discontinue this train. It made its last run, with extra coaches and much fanfare, on March 7, 1953. It had remained a steam train with an ancient wooden combine and one coach almost to the very end, at which time steam power had been taken off and a diesel locomotive substituted.

 

B&M operated through symbol freights Worcester to Mechanicville, NY (WM-1), and Mechanicville, NY, to Worcester (WM-2), as well as a local freight that switched customers between Worcester and Gardner. The through freights between Worcester and Mechanicville, NY, operated until about 1968. WM-1 would arrive punctually in Holden at 7:30 every evening, switch the small yard, and then depart for Gardner and points west. The eastbound WM-2 passed through in the small hours of the night. The local switcher out of Worcester worked during the day. By the end of B&M control, through service on the line had been discontinued and the Worcester switcher ventured out the line only to service customers as needed.

 

The line underwent a dramatic renaissance when the P&W commenced operations in 1974. The P&W rehabilitated the line and operates through freights from Providence, RI, and other southern New England points to Gardner, where traffic is interchanged with the B&M. Currently (2005), P&W runs about six trains each way through Holden weekly, hauling coal, lumber, scrap iron, paper goods, plastic resins and other commodities.

 

Currently there are no customers receiving or shipping by rail in Holden.

Building a new tramway through city streets has always been disruptive, and the return of trams to Manchester in the early 1990s was no exception. Here, the new track and station at the top of Market Street are being built, and as you can see there's quite a lot of building work going on.

 

Only one track has been laid so far, to allow buses to travel along Market Street for a while. In the background we can see buses of GM Buses and Stuart''s of Hyde plying their trade.

 

The photo is one of a set taken to show the progress of construction before the system's first phase opened in April 1992.

 

If you'd like to know more about the Manchester Museum of Transport and its collection of vintage buses, go to www.gmts.co.uk.

  

The SpaceX Falcon 9 rocket with the company's Crew Dragon spacecraft onboard is seen on the launch pad at Launch Complex 39A as preparations continue for the Demo-1 mission, Friday, March 1, 2019 at the Kennedy Space Center in Florida. The Demo-1 mission will be the first launch of a commercially built and operated American spacecraft and space system designed for humans as part of NASA's Commercial Crew Program. The mission, currently targeted for a 2:49am launch on March 2, will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Joel Kowsky)

A United Launch Alliance Atlas V rocket with Boeing’s CST-100 Starliner spacecraft aboard is seen as it is rolled out of the Vertical Integration Facility to the launch pad at Space Launch Complex 41 ahead of the Orbital Flight Test-2 (OFT-2) mission, Wednesday, May 18, 2022 at Cape Canaveral Space Force Station in Florida. Boeing’s Orbital Flight Test-2 will be Starliner’s second uncrewed flight test and will dock to the International Space Station as part of NASA's Commercial Crew Program. The mission, currently targeted for launch at 6:54 p.m. ET on May 19, will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Joel Kowsky)

Gare de Bourg-Saint-Maurice 20/01/2018 13h10

This TGV Euro Duplex en tête is ready for departure as TGV 6426 to Paris Gare de Lyon departure time 13h13. At the rear connected with TGV set 201. The 812 is a TGV Duplex of the new generation, Euro TGV, built by Alstom in 2014.

 

TGV Duplex

The TGV Duplex is a French high-speed train of the TGV family, manufactured by Alstom, and operated by the French national railway company SNCF. It is unique among TGV trains in that it features bi-level carriages. The Duplex inaugurated the third generation of TGV trainsets. It was specially designed to increase capacity on high-speed lines with saturated traffic. With two seating levels and a seating capacity of 508 passengers, the Duplex increases the passenger capacity. While the TGV Duplex started as a small component of the TGV fleet, it has become one of the system's workhorses.

 

FACTS & FIGURES

Manufacturer: GEC-Alsthom, Alstom

Constructed: 1995–2012

Numbers built:

- 89 trainsets (Duplex), fleetnumbers 201 - 289 (built 1995 - 2006)

- 52 trainsets (Dasye), fleetnumbers 701-720 & 733-749 & 760-772

- 19 trainsets Reseau Duplex, fleetnumbers 601-619 (built 2009-2012)

- 55 TGV 2N2 Euroduplex, fleetnumbers 801-825 & 4701 - 4730 (built 2011 - 2019)

Formation: 10 cars (2 power cars, 8 passenger cars)

Capacity: 508 seats

Train length: 200 m

Maximum speed: 320 km/h

[ Source and more Information: Wikipedia - TGV Duplex ]

A United Launch Alliance Atlas V rocket with Boeing’s CST-100 Starliner spacecraft aboard launches from Space Launch Complex 41, Thursday, May 19, 2022, at Cape Canaveral Space Force Station in Florida. Boeing’s Orbital Flight Test-2 (OFT-2) is Starliner’s second uncrewed flight test and will dock to the International Space Station as part of NASA's Commercial Crew Program. OFT-2 launched at 6:54 p.m. ET, and will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Joel Kowsky)

"Shinrin-yoku is a term that means "taking in the forest atmosphere" or "forest bathing." It was developed in Japan during the 1980s and has become a cornerstone of preventive health care and healing in Japanese medicine. Researchers primarily in Japan and South Korea have established a robust body of scientific literature on the health benefits of spending time under the canopy of a living forest. Now their research is helping to establish shinrin-yoku and forest therapy throughout the world.

 

We have always known intuitively that time in nature is good for us. But in the past several decades there have been many scientific studies that are demonstrating the mechanisms behind the healing effects of simply being in wild and natural areas. For example, many trees give off organic compounds and essential oils that support our “NK” (natural killer) cells that are part of our immune system's way of fighting cancer and heart disease.

 

The scientifically-proven benefits of Shinrin-yoku include:

 

Lowered blood pressure

Lowered pulse rate

Reduced cortisol levels

Increased vigor

Reduced anger

Reduced depression."

 

Shinrin-yoku.org

 

Then, again, some of us just do it because we like it. This is the Mickey Hill Wilderness Area in Nova Scotia yesterday afternoon.

 

Red-footed Boobies on the old seawall. Tern Island in the French Frigate Shoals, Hawaii.

 

Camera: Olympus OM-1

Lens: Olympus OM-System S Zuiko MC Auto-Zoom f/4 35-70mm. Yellow filter.

Film: Adox HR-50

Developer: Beerenol (Rainier Beer)

A United Launch Alliance Atlas V rocket with Boeing’s CST-100 Starliner spacecraft aboard is seen at sunrise on the launch pad at Space Launch Complex 41 ahead of the Orbital Flight Test-2 mission, Tuesday, Aug. 3, 2021 at Cape Canaveral Space Force Station in Florida. Boeing’s Orbital Flight Test-2 will be Starliner’s second uncrewed flight test and will dock to the International Space Station as part of NASA's Commercial Crew Program. The mission, currently targeted for launch at 1:20 p.m. EDT, will serve as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Aubrey Gemignani)

System's Hot Legs.

 

Police Parade in Warsaw

 

Plac Józefa Piłsudskiego, Warsaw, July 24th, 2009

 

Digital, Mark II, 24-70 Canon Zoom Lens, 21 MgPx

NASA astronaut and Crew Recovery Chief Shannon Walker, center, and other NASA and Boeing teams listen to Boeing Starliner Launch Conductor Louis Atchison as they prepare for the landing of Boeing’s CST-100 Starliner spacecraft at White Sands Missile Range’s Space Harbor, Wednesday, May 25, 2022, in New Mexico. Boeing’s Orbital Flight Test-2 (OFT-2) is Starliner’s second uncrewed flight test to the International Space Station as part of NASA's Commercial Crew Program. OFT-2 serves as an end-to-end test of the system's capabilities. Photo Credit: (NASA/Bill Ingalls)

Workers inside the Astrotech Space Operations Facility in Titusville, Florida, move the first half of the United Launch Alliance (ULA) payload fairing toward NASA’s Lucy spacecraft on Sept. 30, 2021. The payload fairing will encapsulate and protect the spacecraft during launch and ascent. Lucy is scheduled to launch no earlier than Saturday, Oct. 16, on a ULA Atlas V 401 rocket from Space Launch Complex 41 at Cape Canaveral Space Force Station. NASA’s Launch Services Program based at Kennedy Space Center is managing the launch. Over its 12-year primary mission, Lucy will explore a record-breaking number of asteroids, flying by one asteroid in the solar system’s main belt and seven Trojan asteroids. Additionally, Lucy’s path will circle back to Earth three times for gravity assists, making it the first spacecraft ever to return to the vicinity of Earth from the outer solar system. Photo credit: NASA/Ben Smegelsky

NASA image use policy.

 

The NASA/ESA/CSA James Webb Space Telescope has captured new details of the auroras on our Solar System’s largest planet. The dancing lights observed on Jupiter are hundreds of times brighter than those seen on Earth.

 

These observations of Jupiter’s auroras were captured with Webb’s Near-InfraRed Camera (NIRCam) on 25 December 2023 (F335M filter). Scientists found that the emission from the trihydrogen ion, known as H3+, is far more variable than previously believed. H3+ is created by the impact of high energy electrons on molecular hydrogen. Because this emission shines brightly in the infrared, Webb’s instruments are well equipped to observe it.

 

A video of these observations can be found here.

 

[Image description: Three panels, each showing a close-up near-infrared image of Jupiter’s north pole, in shades of orange. The planet is mostly dark. Thick, bright arcs and rings caused by aurorae cover the pole. The centre and right panels each show the aurora a few minutes later in time, as Webb’s field of view slowly scans over the planet.]

 

Read more

 

Credits: ESA/Webb, NASA, CSA, J. Nichols (University of Leicester), M. Zamani (ESA/Webb); CC BY 4.0